Search results for "Rectal Cancer"

showing 10 items of 978 documents

Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials ( LICC , CEL…

2021

Metastatic colorectal cancer (mCRC) patients with liver-limited disease (LLD) have a chance of long-term survival and potential cure after hepatic metastasectomy. However, the appropriate postoperative treatment strategy is still controversial. The CELIM and FIRE-3 studies demonstrated that secondary hepatic resection significantly improved overall survival. The objective of this analysis was to compare these favorable outcome data with recent results from the LICC trial investigating the antigen-specific cancer vaccine tecemotide (L-BLP-25) as adjuvant therapy in mCRC patients with LLD after R0/R1 resection. Data from mCRC patients with LLD and secondary hepatic resection from each study w…

Cancer Researchmedicine.medical_specialtyColorectal cancerbusiness.industryDiseasemedicine.diseaseResectionSurgeryOncologyCohortmedicineAdjuvant therapyTecemotideCancer vaccineMetastasectomybusinessInternational Journal of Cancer
researchProduct

In the literature: April 2017

2017

The full publication in Lancet Oncology of the Stockholm III trial helps us to understand that short-course radiotherapy in patients with localised rectal cancer could also be followed by delayed surgery.1 During more than 14 years, more than 800 patients with rectal cancer not showing unresectable features were randomised in a two-arm versus three-arm study with a non-inferiority design. Patients could be randomised to short-course radiotherapy (5×5 Gy) and immediate (within a week) versus delayed (4–8 weeks) surgery. In the three-arm randomisation patients could also be allocated to a long course of concurrent chemoradiation (25×2 Gy), with surgery performed 6–8 weeks thereafter. Time to …

Cancer Researchmedicine.medical_specialtyColorectal cancerbusiness.industrymedicine.medical_treatmentPostoperative complicationConcurrent chemoradiationNewsmedicine.diseaseSurgeryRadiation therapyOncologyLiteratureClinical endpointmedicineDelayed surgeryIn patient1506businessESMO Open
researchProduct

Factors Associated with Prolonged Patient-Attributable Delay in the Diagnosis of Colorectal Cancer

2018

Purpose The delayed diagnosis of colorectal cancer (CRC) may be attributable to sociodemographic characteristics, to aspects of tumour histopathology or to the functioning of the health system. We seek to determine which of these factors most influences prolonged patient-attributable delay (PPAD) in the diagnosis and treatment of CRC. Materials and methods A prospective, multicentre observational study was conducted in 22 Spanish hospitals. In total, 1,785 patients were recruited to the study between 2010 and 2012 and underwent elective or urgent surgery. PPAD is considered to occur when the time elapsed between a patient presenting the symptom and him/her seeking attention from the primary…

Cancer Researchmedicine.medical_specialtyDelayed DiagnosisPatientsColorectal cancerPopulationLogistic regressionColorectal neoplasms03 medical and health sciences0302 clinical medicineSex FactorsRisk FactorsInternal medicineDiagnosismedicineHumans030212 general & internal medicineProspective StudieseducationEmergency TreatmentAgedAged 80 and overeducation.field_of_studyDelaybusiness.industryPrimary care physicianAge FactorsOdds ratioEmergency departmentMiddle Agedmedicine.diseaseConfidence intervalCross-Sectional StudiesLogistic ModelsOncologyElective Surgical Procedures030220 oncology & carcinogenesisObservational studyOriginal ArticleFemalebusinessCancer Research and Treatment : Official Journal of Korean Cancer Association
researchProduct

Incidence and patterns of late recurrences in colon cancer patients

2015

Long-term recurrences of colon cancer raised questions about the possible benefit of prolonging the recommended active 5-year surveillance. The aim of this study was to determine, for the first time, the incidence and patterns of late 10-year recurrence following curative resection of colon cancer. Data were obtained from two French digestive cancer registries. A total of 3,622 patients under 85 years resected for cure for colon cancer diagnosed between 1985 and 2000 were included. Information regarding recurrences was actively collected. Cumulative failure rates at 10 years were estimated using Kaplan-Meier estimates corrected by cause-specific hazards, and multivariable analysis was perfo…

Cancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerbusiness.industryIncidence (epidemiology)Female sexLower riskCompeting risksmedicine.diseaseSurgeryCancer registryOncologyColon cancer resectionmedicinebusinessInternational Journal of Cancer
researchProduct

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Inten…

2015

Objective Intensified preoperative treatments have been increasingly investigated in locally advanced rectal cancer (LARC), but limited data are available for the impact of these regimens on quality of life (QoL) and bowel function (BF). We assessed these outcome measures in EXPERT-C, a randomized phase 2 trial of neoadjuvant capecitabine combined with oxaliplatin (CAPOX), followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab in magnetic resonance imaging-defined, high-risk LARC. Methods and Materials QoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR29 questionnaires. Bowel inc…

Cancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerHealth StatusCetuximabAntineoplastic AgentsUrinary incontinenceBowel incontinenceSeverity of Illness Indexlaw.inventionRandomized controlled trialQuality of lifelawSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansFecal incontinenceRadiology Nuclear Medicine and imagingSexual Dysfunctions PsychologicalCapecitabineRadiationRectal Neoplasmsbusiness.industryRectumChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingTotal mesorectal excisionNeoadjuvant TherapyhumanitiesSurgeryOxaliplatinOncologyChemotherapy AdjuvantQuality of Lifemedicine.symptombusinessFecal IncontinenceChemoradiotherapyInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Breath testing as potential colorectal cancer screening tool

2015

Although colorectal cancer (CRC) screening is included in organized programs of many countries worldwide, there is still a place for better screening tools. In this study, 418 breath samples were collected from 65 patients with CRC, 22 with advanced or nonadvanced adenomas, and 122 control cases. All patients, including the controls, had undergone colonoscopy. The samples were analysed with two different techniques. The first technique relied on gas chromatography coupled with mass spectrometry (GC-MS) for identification and quantification of volatile organic compounds (VOCs). The T-test was used to identify significant VOCs (p values < 0.017). The second technique relied on sensor analysis…

Cancer Researchmedicine.medical_specialtyPathologymedicine.diagnostic_testAdenomaCrc screeningColorectal cancerbusiness.industryColonoscopymedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicineBreath testingOncologyColorectal cancer screening030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyScreening toolbusinessInternational Journal of Cancer
researchProduct

Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure

2013

Colorectal cancer is one of the major causes of cancer mortality in the elderly population (median age at diagnosis of 71 years) in Western Countries. Moreover patients with metastatic disease are often elderly with significant co- morbidities. Unfortunately, elderly patients are often untreated and under-represented in clinical trials, even if most clinical trials that have included this setting of population have shown similar survival rates and toxicities to younger patients. Age itself should not be considered for candidacy to chemotherapy but it should be taken in consideration the great heterogeneity of co-morbidities present in the elderly population. Therefore, the best treatment st…

Cancer Researchmedicine.medical_specialtyPediatricsColorectal cancerhealth care facilities manpower and servicesPopulationDiseaseCancer; Chemotherapy; Colorectal; Elderly; TreatmentCauses of cancerElderlyAntineoplastic Combined Chemotherapy Protocols80 and overmedicineHumansChemotherapyAdverse effecteducationColorectalAgedQuality of Health CareCancerAged 80 and overPharmacologyeducation.field_of_studybusiness.industryCancersocial sciencesmedicine.diseasehumanitiesAged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Quality of Health CareTreatmentClinical trialPhysical therapyCandidacyMolecular MedicineColorectal NeoplasmsbusinessAnti-Cancer Agents in Medicinal Chemistry
researchProduct

A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with c…

2013

TPS3124^ Background: 15-20% of all patients (pts) diagnosed with colorectal cancer (crc) develop metastases (mets) surgical resection remains the only potentially curative treatment available. Current 5-year survival rate following R0 resection of liver mets lies between 28-39%, recurrence occurs in up to 70% of pts. To date, adjuvant chemotherapy has not significantly improved clinical outcomes. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active MUC1-specific cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in crc pts following R0/R1 resection of liver mets known to highly express MUC1 gly…

Cancer Researchmedicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentImmunotherapymedicine.diseasePlaceboGastroenterologySurgeryDouble blindOncologyCurative treatmentInternal medicineMedicineTecemotideIn patientMetastasectomybusinessJournal of Clinical Oncology
researchProduct

Recent cancer survival in Germany: An analysis of common and less common cancers

2014

The monitoring of cancer survival by population-based cancer registries is a prerequisite to evaluate the current quality of cancer care. Our study provides 1-, 5- and 10-year relative survival as well as 5-year relative survival conditional on 1-year survival estimates and recent survival trends for Germany using data from 11 population-based cancer registries, covering around one-third of the German population. Period analysis was used to estimate relative survival for 24 common and 11 less common cancer sites for the period 2007-2010. The German and the United States survival estimates were compared using the Surveillance, Epidemiology and End Results 13 database. Trends in cancer surviv…

Cancer Researchmedicine.medical_specialtyeducation.field_of_studyRelative survivalColorectal cancerbusiness.industryPopulationCancermedicine.diseaseSurgeryCancer registryProstate cancerOncologyEpidemiologymedicineeducationbusinessMultiple myelomaDemographyInternational Journal of Cancer
researchProduct

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

2022

Lynch syndrome (LS) is an inherited genetic condition associated with increased predisposition to colorectal cancer (CRC) and other tumors and is caused by germline mutations in Mismatch Repair (MMR) or EPCAM genes. The identification of LS carriers is currently based on germline testing of subjects with MMR-deficient (dMMR) tumors or fulfilling clinical criteria, but the most efficient strategies to select patients who should be offered genetic testing are yet not well defined. In order to assess the most suitable selection mode to identify LS-related CRC patients, we retrospectively collected and analyzed all clinical and molecular information of 854 CRC patients, recruited from 2013 to 2…

Cancer Researchmismatch repair genesSettore MED/06 - Oncologia MedicaMMR-deficiency[SDV]Life Sciences [q-bio]MLH1Neoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal cancerdigestive system diseasesMSH2Lynch syndromeOncologygermline mutationsmicrosatellite instabilityRC254-282Frontiers in Oncology
researchProduct